CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← Novo Nordisk A/S (NVO) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

Novo Nordisk A/S (NVO)

Pharmaceutical Preparations · market cap $169.8B · as of 2026-10-16

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
2026-12-14 (est.)
Phase 2
Pipeline
20
programs
Upcoming events
8
next 90d+
Dossier
Ready
cached
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
Novo Nordisk is a Danish pharmaceutical company with a $169.8B market cap, about 66,700 employees, and a broad late-stage pipeline spanning diabetes, obesity, cardiovascular, haemophilia/rare bleeding, and sickle cell disease. Novo Holdings holds about 28.1% of the shares and 77.1% of the votes, so this is a controlled company. The near-term setup is a dense run of Phase 3 readouts concentrated in January to March 2027, including Ziltivekimab, Insulin Icodec, and CagriSema, set against reported revenue growth that slowed to roughly 6% in 2025.
The catalyst path
  • 2026-12-14 (est.)Phase 2 · NNC0662-0419imp 7/10
  • 2026-12-31 (est.)NDA Filing · Etavopivatimp 8/10
  • 2027-01-14 (est.)Phase 2 · UBT251imp 7/10
  • 2027-01-25 (est.)Phase 3 · Insulin Icodecimp 9/10
  • 2027-01-29 (est.)Phase 3 · Ziltivekimabimp 9/10
  • 2027-03-01 (est.)Phase 3 · CagriSema (Cagrilintide B and Semaglutide I)imp 9/10
  • 2027-04-01 (est.)Otherimp 6/10
  • 2027-05-12 (est.)Phase 3 · Cagrilintideimp 9/10
Pipeline
AssetPhaseIndication
NNC6019-0001Phase 3Transthyretin Amyloid Cardiomyopathy (ATTR CM)
CDR132LPhase 2Heart Failure
biphasic insulin aspartPhase 3Diabetes
NNC109-0012Phase 2Inflammation
CagrilintidePhase 3Obesity or Overweight
ConcizumabPhase 3Congenital Bleeding Disorder
biphasic human insulinPhase 3Diabetes
Insulin IcodecPhase 3Diabetes Mellitus, Type 2
Semaglutide (administered by PDS290 pen)Phase 2Healthy Volunteers Diabetes Mellitus, Type 2
human insulinPhase 3Diabetes
insulin 338 (GIPET I)Phase 2Diabetes
insulin NPHPhase 3Diabetes
NNC0662-0419Phase 2Overweight
turoctocog alfa pegolPhase 3Congenital Bleeding Disorder
rosiglitazonePhase 3Diabetes
biphasic insulin aspart 50Phase 3Diabetes
DPP-4 inhibitorPhase 3Diabetes
NNC0365-3769 (Mim8)Phase 3Haemophilia A
Norditropin®Phase 3Growth Hormone Deficiency in Children
Ziltivekimab BPhase 3Cardiovascular Risk
Price & technical context
3-month
-8.3%
6-month
-5.3%
12-month
-14.7%
52-wk range
$35.29–$63.98
vs 50-day MA
+4.8%
vs 200-day MA
-2.7%
Realized vol
46.2%
Max drawdown
-69.7%

Daily closes through 2026-11-16. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for NVO (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.